Drug delivery techniques for treating age-related macular degeneration

Expert Opinion on Drug Delivery

Volumn 11, Issue 1, 2014, Pages 61-68

  Schwartz, Stephen G ^a   Scott, Ingrid U ^b   Flynn Jr , Harry W ^a   Stewart, Michael W ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Intravitreal injection; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; LIPOSOME; NANOPARTICLE; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; DELAYED RELEASE FORMULATION; VASCULOTROPIN A;

DRUG DELIVERY SYSTEM; ENDOPHTHALMITIS; HUMAN; INTRAVITREAL IMPLANT; NON INVASIVE PROCEDURE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUSTAINED DRUG RELEASE; ADMINISTRATION AND DOSAGE; ANIMAL; ANTAGONISTS AND INHIBITORS; DELAYED RELEASE FORMULATION; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84890643919     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.859135     Document Type: Review

References (76)

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-51
2. Nowak JZ. Age-related macular degeneration (AMD): Pathogenesis and therapy. Pharmacol Rep 2006;58:353-63
3. Ghate D, Edelhauser HF. Ocular drug delivery. Expert Opin Drug Deliv 2006;3:275-87
4. Kovach JL, Schwartz SG, Flynn HW Jr, Scott IU. Anti-VEGF treatment strategies for wet AMD. J Ophthalmol 2012;doi:10.1155/2012/786870
5. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-47
6. Hurwitz HI, Tebbutt NC, Kabbinavar F, et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: Pooled analysis from seven randomized controlled trials. Oncologist 2013;18(9):1004-12
7. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-Administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:1522.e1-1522.e14
8. Nussenblatt RB, Byrnes G, Sen HN, et al. A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. Retina 2010;30:1579-87
9. Wong WT, Dresner S, Forooghian F, et al. Treatment of geographic atrophy with subconjunctival sirolimus: Results of a phase I/II clinical trial. Invest Ophthalmol Vis Sci 2013;54:2941-50
10. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16
11. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2006;355:1419-31
12. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48
13. CATT Research Group. Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364(20):1897-908
14. Schwartz SG, Flynn HW, Scott IU. Endophthalmitis after intravitreal injections. Expert Opin Pharmacother 2009;10:2119-26
15. Sharma S, Johnson D, Abouammoh M, et al. Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol 2012;47:275-9
16. Forooghian F, Cukras C, Meyerle CB, et al. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 2009;29:723-31
17. Pershing S, Bakri SJ, Moshfeghi DM. Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina 2013;44:460-4
18. Mansour AM, Shahin M, Kofoed PK, et al. Insight into 144 patients with ocular vascular events during VEGF antagonist injections. Clin Ophthalmol 2012;6:343-63
19. Kumar A, Sehra SV, Thirumalesh MB, Gogia V. Secondary rhegmatogenous retinal detachment following intravitreal bevacizumab in patients with vitreous hemorrhage or tractional retinal detachment secondary to Eales' disease. Graefes Arch Clin Exp Ophthalmol 2012;250:685-90
20. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol 2010;21:178-83
21. Day S, Acquah K, Lee PP, et al. Medicare costs for neovascular age-related macular degeneration, 1994-2007. Am J Ophthalmol 2011;152:1014-20
22. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58
23. Engelbert M, Zweifel SA, Freund KB. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/ retinal angiomatous proliferation. Retina 2009;29:1424-31
24. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology 2012;1388-98
25. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382(9900):1258-67
26. Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endogenous VEGF is required for visual function: Evidence for a survival role on Muller cells and photoreceptors. PLoS ONE 2008;3:e3554
27. Grisanti S, Tatar O. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 2008;27:372-90
28. Rosenfeld PJ, Shapiro H, Tuomi L, et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 2011;118:523-30
29. Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2013;Epub ahead of print
30. Kompella UB, Kadam RS, Lee VH. Recent advances in ophthalmic drug delivery. Ther Deliv 2010;1:435-56
31. Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: Twelve-month study results. Ophthalmology 2011;118:2453-60
32. Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for non-infectious intermediate or posterior uveitis. Arch Ophthalmol 2011;129:545-53
33. Callanan DG, Jaffe GJ, Martin DA, et al. Treatment of posterior uveitis with a fluocinolone implant: Three-year clinical trial results. Arch Ophthalmol 2008;126:1191-201
34. Schwartz SG, Flynn HW Jr. Fluocinolone acetonide implantable device for diabetic retinopathy. Curr Pharm Biotechnol 2011;12:347-51
35. Maurice D. Review: Practical issues in intravitreal drug delivery. J Ocul Pharmacol Ther 2001;17:393-401
36. Macugen AMD Study Group. Apte RS, Modi M, Masonson H, et al. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 2007;114:1702-12
37. Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 2012;154:682-6
38. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008;146:508-12
39. Christofiridis JB, Williams MM, Kothandaraman S, et al. Pharmacokinetic properties of intravitreal I-124-Aflibercept in a rabbit model using PET/CT. Curr Eye Res 2012;37:1171-4
40. Stewart MW. What are the half-lives of ranibizumab and aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical model. Eye Rep 2011;1:e5
41. Ramos-Cabrer P, Campos F. Liposomes and nanotechnology in drug development: Focus on neurological targets. Int J Nanomedicine 2013;8:951-60
42. del Pozo-Rodriguez A, Delgado D, Gascon AR, Solinis MA. Lipid nanoparticles as drug/gene delivery systems to the retina. J Ocul Pharmacol Ther 2013;29:173-88
43. Pescina S, Ferrari G, Govoni P, et al. In-vitro permeation of bevacizumab through human sclera: Effect of iontophoresis application. J Pharm Pharmacol 2010;62:1189-94
44. Eljarrat-Binstock E, Domb AJ, Orucov F, et al. Methotrexate delivery to the eye using transscleral hydrogel iontophoresis. Curr Eye Res 2007;32:639-46
45. Patane MA, Schubert W, Sanford T, et al. Evaluation and general safety following repeated dosing of dexamethasone phosphate delivered by transscleral iontophoresis in rabbits. J Ocul Pharmacol Ther 2013;29(8):760-9
46. Singh RP, Mathews ME, Kaufman M, Riga A. Transcleral delivery of triamcinolone acetonide and ranibizumab to retinal tissues using macroesis. Br J Ophthalmol 2010;94:170-3
47. Schultz C, Breaux J, Schentag J, Morck D. Drug delivery to the posterior segment of the eye through hydrogel contact lenses. Clin Exp Optom 2011;94:212-18
48. Tetz M, Rizzo S, Augustin AJ. Safety of submacular suprachoroidal drug administration via a microcatheter: Retrospective analysis of European treatment results. Ophthalmologica 2012;227:183-9
49. Patel SR, Berezovsky DE, McCarey BE, et al. Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. Invest Ophthalmol Vis Sci 2012;53:4433-41
50. Campochiaro PA. Gene transfer for ocular neovascularization and macular edema. Gene Ther 2012;19:121-6
51. El Sanharawi M, Touchard E, Benard R, et al. Long-Term efficacy of ciliary muscle gene transfer of three sFLt-1 variants in a rat model of laser-induced choroidal neovascularization. Gene Ther 2013;Epub ahead of print
52. Kauper K, McGovern C, Sherman S, et al. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Invest Ophthalmol Vis Sci 2012;53:7894-1
53. Gooch N, Burr RM, Holt DJ, et al. Design and in vitro biocompatibility of a novel ocular drug delivery device. J Funct Biomater 2013;4:14-26
54. Loewenstein A. Refillable drug delivery implant providing sustained release anti-VEGF therapy in wet AMD. Angiogenesis, exudation, and degeneration. Miami, FL: 2013
55. Stevenson CL, Santini JT Jr, Langer R. Reservoir-based drug delivery systems utilizing microtechnology. Adv Drug Deliv Rev 2012;64:1590-602
56. Bakri SJ, Snyder MR, Pulido JS, et al. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 2006;26:519-22
57. Zaman RT, Gopal A, Starr K, et al. Micro-patterned drug delivery device for light-Activated drug release. Laser Surg Med 2012;44:30-48
58. Saati S, Lo R, Li PY, et al. Mini drug pump for ophthalmic use. Trans Am Ophthalmol Soc 2009;107:60-70
59. Honda M, Asai T, Oku N, et al. Liposomes and nanotechnology in drug development: Focus on ocular targets. Int J Nanomedicine 2013;8:495-503
60. Koc A, Onal S, Yenice O, Kazokoglu H. Pars plana vitrectomy and intravitreal liposomal amphotericin B in the treatment of Candida endophthalmitis. Ophthalmic Surg Lasers Imaging 2010;doi:10.3928/1542887- 20100215-35
61. Honda M, Asai T, Umemoto T, et al. Suppression of choroidal neovascularization by intravitreal injection of liposomal SU5416. Arch Ophthlamol 2011;129:317-21
62. Abrishami M, Zarei-Ghanavati S, Souroush D, et al. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (Avastin) for intravitreal administration. Retina 2009;29:699-703
63. Farjo KM, Ma JX. The potential of nanomedicine therapies to treat neovascular disease in the retina. J Angiogenesis Res 2010;2:21
64. Kompella UB, Amrite AC, Pacha Ravi R, Durazo SA. Nanomedicines for the back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res 2013;172-98
65. Carrasquillo KG, Ricker JA, Rigas IK, et al. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lacticco-glycolic)acid microspheres. Invest Ophthalmol Vis Sci 2003;44:290-9
66. Shelke NB, Kadam R, Tyagi P, et al. Intravitreal poly(L-lactide) microparticles sustain retinal and choroidal delivery of TG-0054, a hydrophilic drug intended for neovascular diseases. Drug Deliv Transl Res 2011;1:76-90
67. Mukherjee P, Bhattacharya R,Wang P, et al. Antiangiogenic properties of gold nanoparticles. Clin Cancer Res 2005;11:3530-4
68. Kim JH, Kim MH, Jo DH, et al. The inhibition of retinal neovascularization by gold nanoparticles via suppression of VEGFR-2 activation. Biomaterials 2011;32:1865-71
69. Shmueli RB, Ohnaka M, Miki A, et al. Long-Term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide. Biomaterials 2013;34:7544-51
70. Araujo G, Garcia ML, Mallandrich M, et al. Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TANLC): In vitro and ex vivo studies. Nanomedicine 2012;8:1034-41
71. Pan CK, Durairaj C, Kompella UB, et al. Comparison of long-Acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J Ocul Pharmacol Ther 2011;27:219-24
72. Marano RJ, Toth I, Wimmer N, et al. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: A long-Term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther 2005;12:1544-50
73. Iezzi R, Guru BR, Glybina IV, et al. Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials 2012;33:979-88
74. Kang Derwent JJ, Mieler WF. Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye. Trans Am Ophthalmol Soc 2008;106:206-13
75. Wang CH, Hwang YS, Chiang PR, et al. Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel. Biomacromolecules 2012;13:40-8
76. Campochiaro PA. Ocular neovascularization. J Mol Med (Berl) 2013;91(3):311-21